日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CD40L and IL-4 lymph node-associated signals protect B cells from rituximab-induced ADCC via KIR and NKG2A

CD40L 和 IL-4 淋巴结相关信号通过 KIR 和 NKG2A 保护 B 细胞免受利妥昔单抗诱导的 ADCC 损伤。

Graham, Lara V; Foxall, Russell B; Ashton-Key, Margaret; Khakoo, Salim I; Sayegh, Souraya; Leandro, Maria; Reddy, Venkat R; Cragg, Mark S; Blunt, Matthew D

Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy

利用多价性和FcγRIIB结合来增强抗CD27免疫疗法

Widdess, Marcus A; Pakidi, Anastasia; Metcalfe, Hannah J; Chan, H T Claude; Inzhelevskaya, Tatyana; Penfold, Chris A; Mockridge, C Ian; Booth, Steven G; James, Sonya; Lim, Sean H; Beers, Stephen A; Cragg, Mark S; Al-Shamkhani, Aymen

CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial

CD27激动剂抗体通过肿瘤内刺激介导B细胞恶性肿瘤的临床反应:多中心RiVa试验

Buermann, Lara E; Stanton, Louise; Rose-Zerilli, Matthew J J; Thorne, Kerensa; Coleman, Adam; Turaj, Anna H; Caddy, Joshua; Wignall, Christopher; Keyworth, Nicole; Konn, Zoe; McKay, Pamela; Osborne, Wendy; Linton, Kim; Medd, Patrick; Lown, Robert; Davies, Andrew J; Johnson, Peter W M; Al-Shamkhani, Aymen; Cragg, Mark S; Collins, Graham P; Keler, Tibor; Yellin, Michael; Gentles, Andrew J; Griffiths, Gareth; Lim, Sean H

Therapeutic targeting of tumour-associated macrophage receptors

肿瘤相关巨噬细胞受体的治疗靶向

Gomes Alves Martins, Rosa; Tekin, Mehmet M; Cragg, Mark S; Roghanian, Ali

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis

CD40L 和 IL-4 通过 HLA-E:NKG2A 轴抑制 NK 细胞介导的抗体依赖性细胞毒性作用。

Graham, Lara V; Horehajova, Ludmila; Haselager, Marco V; Fisher, Jack G; Roos, Jamie Lee; Foxall, Russell B; John, Mel; Cox, Kerry L; Oldham, Robert J; Taylor, Martin C; Ashton-Key, Margaret; Sale, Ben; Bartlett, Laura G; Roghanian, Ali; Eldering, Eric; Vallejo, Andres F; Forconi, Francesco; Khakoo, Salim I; Cragg, Mark S; Blunt, Matthew D

FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs

FcγRIIB (CD32B) 抗体通过激活 FcγR 增强免疫反应

Simpson, Alexander P; Oldham, Robert J; Cox, Kerry L; Taylor, Martin C; James, Sonya; White, Ann L; Bogdanov, Yury; Glennie, Martin J; Frendeus, Björn; Cragg, Mark S; Roghanian, Ali

The ETS-family transcription factor PU.1 is a critical regulator of the inhibitory Fcγ receptor IIB expression in humans.

ETS家族转录因子PU.1是人类抑制性Fcγ受体IIB表达的关键调节因子

Carter Matthew J, Bogdanov Yury D, Smith Rosanna C, Cox Kerry L, Frampton Sarah, Ferson Lili, Foxall Russel B, Hussain Khiyam, Strefford Jonathan C, Beers Stephen A, Cragg Mark S

Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity

可溶性CTLA-4可减弱T细胞活化并调节抗肿瘤免疫

Kennedy, Paul T; Saulters, Emma L; Duckworth, Andrew D; Lim, Yeong Jer; Woolley, John F; Slupsky, Joseph R; Cragg, Mark S; Ward, Frank J; Dahal, Lekh N

Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges

癌症免疫疗法中的激动剂抗体:历史、希望与挑战

Lim, Sean H; Beers, Stephen A; Al-Shamkhani, Aymen; Cragg, Mark S

Fc gamma receptors: Their evolution, genomic architecture, genetic variation, and impact on human disease

Fcγ受体:它们的进化、基因组结构、遗传变异及其对人类疾病的影响

Frampton, Sarah; Smith, Rosanna; Ferson, Lili; Gibson, Jane; Hollox, Edward J; Cragg, Mark S; Strefford, Jonathan C